



<http://researchspace.auckland.ac.nz>

ResearchSpace@Auckland

Copyright Statement

The digital copy of this thesis is protected by the Copyright Act 1994 (New Zealand).

This thesis may be consulted by you, provided you comply with the provisions of the Act and the following conditions of use:

- Any use you make of these documents or images must be for research or private study purposes only, and you may not make them available to any other person.
- Authors control the copyright of their thesis. You will recognise the author's right to be identified as the author of this thesis, and due acknowledgement will be made to the author where appropriate.
- You will obtain the author's permission before publishing any material from their thesis.

To request permissions please use the Feedback form on our webpage.

<http://researchspace.auckland.ac.nz/feedback>

General copyright and disclaimer

In addition to the above conditions, authors give their consent for the digital copy of their work to be used subject to the conditions specified on the Library Thesis Consent Form.

Molecular Genetics of Idiopathic
Hyperphosphatasia

BELINDA YUEN YEE CHONG

Molecular Genetics and Development
School of Biological Science
University of Auckland



This thesis is submitted in fulfilment of the requirements for the
degree of Doctor of Philosophy

JUNE, 2004

**This thesis is dedicated to my loving parents
David and Christina**

ACKNOWLEDGEMENTS

I would like to thank my supervisors, Dr Don Love and Dr. Tim Cundy. I would like to acknowledge LabPlus, Auckland Hospital the Research Committee of the University of Auckland and the Health Research Council of New Zealand for financial support. Thank you to Graduate Research Fund for providing my travel fund.

I would like to thank the International Hyperphosphatasia Collaborative Group: Madhuri Hegde, Matthew Fawkner, Scott Simonet, Hamilton Cassinelli, Mahmut Coker, John Kanis, Joerg Seidel, Cristina Tau, Beyhan Tüysüz, Bilgin Yüksel, Jill Cornish, Don Love and Tim Cundy for their help with this study. Thanks to Catherin Middleton-Hardie for her help with the NZ family.

I would also like to thank the following people, who at some stage during the three years helped me with practical details, equipment, or materials: To all the people in the Virology and Immunology Department and Cytogenetics Department, Auckland Hospital. I would like to thank Matthew Fawkner for his help and for being so understanding especially during the last few months. Thank you to Dennis Dixon-McIver, Dr Kitty Croxson and John Scott for their help and support.

A very special thanks to Madhuri and her family, Madhuri thanks for all your help and for showing me what true friendship is.

Finally, a very special thanks you to my husband Bruce and my parents, for believing in me and for helping me through everything.

ABSTRACT

The subject of this thesis is the molecular genetic study of idiopathic hyperphosphatasia. The work in this thesis describes linkage analysis, mutation screening of candidate genes and the functional analysis of mutant proteins expressed in patients with a clinical diagnosis of idiopathic hyperphosphatasia.

Idiopathic hyperphosphatasia is an autosomal recessive bone disease characterized by excessive bone resorption and bone formation. Affected children are normal at birth but develop deformities of long bones, kyphosis and acetabular protrusion with increasing severity as they pass through adolescence. There is considerable variability in phenotype, with some cases diagnosed in infancy and others in later childhood. A genome-wide search of a New Zealand family affected by idiopathic hyperphosphatasia suggested linkage to a locus on the long arm of chromosome 8 (8q24). The gene *TNFRSF11B* encoding osteoprotegerin (OPG), which lies within 8q24, was an obvious candidate gene given the critical role of OPG in regulating osteoclast development. Mutation screening of this gene indicated an apparent disease-causing mutation in exon 3 in affected individuals of the New Zealand family. Subsequently eight families, recruited by the members of the Idiopathic Hyperphosphatasia Collaborative Group in Turkey, Germany, Argentina and the United Kingdom were also screened for mutations in the *TNFRSF11B* gene. Recombinant wild-type and mutant OPG cDNAs were expressed in human epithelial kidney cells, and secreted OPG was collected from the conditioned medium. *In vitro* measurements of osteoclastic bone resorption showed that wild type OPG suppressed bone

resorption, whereas the mutant forms did not, confirming them to be inactivating mutations.

TABLE OF CONTENTS

Acknowledgments	i.
Abstract	ii.
Table of Contents	iv.
List of Figures	x.
List of Tables	xii.
Abbreviations and Symbols	xiii.
Company Abbreviations	xv.
Medical Terminology	xvi.
Chapter 1 Introduction	1
1.1 Bone	2
1.2 Bone structure	2
1.2.1 Cortical bone	6
1.2.2 Trabecular bone	7
1.3 Bone function	8
1.3.1 Ossification: Bone formation	8
1.3.1.1 Intramembranous ossification	12
1.3.1.2 Endochondral ossification	13
1.3.2 Homeostasis (remodelling)	14
1.4 The OPG/RANKL/RANK System	21
1.4.1 Interaction of hormones and cytokines on the OPG/RANKL/RANK System	26
1.5 Bone remodelling and disease	30
1.6 Familial Idiopathic Hyperphosphatasia	32
1.7 Thesis overview	37
Chapter 2 Materials and Methods	38
2.1 General	39
2.2 Chemicals	39
2.3 Common buffers and solutions	39
2.4 Collection and handling of specimens	39

2.4.1 Peripheral blood specimens	39
2.4.1 DNA specimens	40
2.5 DNA extraction procedure	40
2.5.1 Puregene DNA extraction procedures (Gentra Inc)	40
2.5.1.1 3 ml whole blood preparation	40
2.5.2 Hypotonic lysis RBC (Buffy coat preparation)	41
2.5.3 Extraction of DNA from buffycoat preparations	42
2.6. Determination of DNA concentration by spectrophotometer	43
2.7 Procedure for checking DNA on agarose gels	44
2.8 Polymerase chain reaction (PCR) kits and buffers used	44
2.9 Preparation of oligonucleotides for PCR	46
2.10 Agarose gel electrophoresis of PCR products	46
2.11 PCR product purification	47
2.11.1 High pure PCR product purification kit (Roche Ltd)	47
2.11.1.1 Purifying amplification products after polymerase chain reaction	47
2.11.1.2 Purifying DNA fragments from agarose gels	47
2.11.2 GFX-96-well PCR purification kit (Amersham Biosciences)	48
2.12 Quantification of PCR templates following purification for sequencing	49
2.13 Automated DNA sequencing	49
2.13.1 Cycle sequencing setup	49
2.13.2 Purification of products following cycle sequencing	50
2.13.2.1 Thin-walled tube method (0.2 ml)	50
2.13.2.2 96-well amplification tray method	50
2.13.3 Electrophoresis of samples on the automated sequencer	51
2.14 Sequence alignment using DNASTar software (LaserGene®)	51
2.15 Biochemical analysis	51
2.16 Genotyping	52
2.16.1 Whole genome scan	52
2.16.2 High density scan	52

2.16.2.1 PCR amplification conditions	52
2.16.2.2 Microsatellite analysis	53
2.17 Procedure for amplification and direct sequencing of amplicons of the TNFRSF11B gene	53
2.18 Transformation of competent cells	54
2.19 Purification of the plasmids (Qiagen® plasmid purification Mega kit)	57
2.20 Wild-type OPG construct (prepared by Dr Dorit Naot, Department of Medicine, University of Auckland)	58
2.21 Construction of mutant OPG cDNAs	59
2.21.1 Site directed mutagenesis	59
2.21.1.1 PCR	59
2.21.1.4 Second round PCR	60
2.21.3 Cloning into pGEM®-T Easy vector using pGEM®-T Easy vector system (Promega)	61
2.21.3.1 Ligation of mutant OPG cDNA constructs into the pGEM®-T Easy vector	61
2.21.5 Cloning of mutant OPG cDNAs into the pcDNA3.1(-)/myc-HisA vector (Invitrogen)	61
2.21.5.1 Restriction enzyme digestion of mutant OPF cDNA/pGEM®-T Easy construct	62
2.21.5.2 Restriction enzyme digestion of pcDNA3.1(-)/myc-HisA plasmid (Invitrogen)	62
2.21.5.3 Ligation of mutant OPG cDNA fragments with pcDNA3.1(-)/myc-HisA vector	63
2.22 Expression of recombinant OPG and mutant OPG	63
2.22.1 Transfection assay	63
2.22.1.1 Preparation of cells for transfection	64
2.22.1.2 Preparation of complex	64
2.22.1.3 Transfection of cells	64
2.22.1.4 Expression of OPG and OPG mutant mRNAs in HEK293	65

transfected cells	
2.22.1.5 Collection of OPG and OPG mutant protein from media	65
2.22.2 ELISA assay (R&D Systems and BioVendor)	65
2.22.2.1 Plate preparation	66
2.22.2.2 Assay procedure	67
2.22.3 Western blot analysis (WesternBreeze® Chemiluminescent Western Blot Immunodetection Kit-Invitrogen)	69
2.22.3.1 Solution preparation	69
2.22.3.2 Procedure	70
2.22.4 Glycosylation assay (Roche Ltd)	71
2.22.4.1 Preparation of solutions	71
2.22.4.2 Procedure for complete deglycosylation	72
2.23 Bioassay measurement of ⁴⁵ Ca release in organ cultures	72
2. 23.1 Concentration of wild-type and mutant proteins	72
2.23.2 Bone resorption assay	72
2.24 Databases	74
CHAPTER 3 Clinical Presentation and Linkage analysis of IH Families	75
3.1 New Zealand family	76
3.1.1 Clinical presentation	76
3.1.2 Whole genome scan	82
3.2 Families recruited by members of the Idiopathic Hyperphosphatasia Collaborative Group	85
3.2.1 Clinical presentation	85
3.2.2 High density genome scan	91
3.2.3 Candidate gene search in databases	95
3.3 Summary	96
Chapter 4 Mutation Screening of the TNFRSF11B Gene	97
4.1 Experimental design and results	98
4.1.1 Genomic DNA and mRNA sequence of the TNFRSF11B gene	98

4.1.2 Primer Design	99
4.2 Exon-by-exon sequencing	102
4.3 Discussion	112
4.3.1 Functionally important domains of the OPG protein	112
4.3.2 Predictions of mutation effects	116
4.3.3 Promoter variants	118
4.3.4 Summary	119
CHAPTER 5 Functional Analysis of the TNFR11B Gene Mutations	120
5.1 Prior work on OPG protein structure and function	121
5.2 Experimental design and results	124
5.2.1 Construction of mutant OPG cDNAs	124
5.2.2 Expression and analysis of wild-type and mutant OPG	131
5.2.3 Organ culture assay (measurement of ⁴⁵ Ca release) of mutant OPGs	133
5.3 Discussion	135
Chapter 6 Discussion	137
6.1 Summary	138
6.2 Genotype:phenotype correlations	139
6.3 Apparent IH patients with no detectable mutation in the TNFRSF11B gene	143
6.4 Disease modelling	144
6.4 Therapy	145
Appendix 1 LOD Score and Database Search Results	147
Appendix 2 Clinical Data Sheet	154
Appendix 3 Promoter Region (Proscan Version 1.7 Search), Exon 1 (AB008821) and Exon 2.5 (AB008822) Sequences	157
Appendix 4 Primer Sequences	167
Appendix 5 Radiographs of Individuals A3, B3 and C1	172
Appendix 6 Analysis of the TNFRSF11A, TNFRSF11 & TGFB Genes	174
References	191

LIST OF FIGURES

- Chapter 1 Introduction**
- Figure 1.1 Schematic views of a longitudinal section through a growing long bone.
- Figure 1.2 Histology of osseous tissue (bone).
- Figure 1.3 Electron micrograph of an osteocyte.
- Figure 1.4 von Kossa stain of iliac bone.
- Figure 1.5 Goldner trichrome stain of iliac bone.
- Figure 1.6 Intramembranous ossification.
- Figure 1.7 Endochondrial ossification.
- Figure 1.8 Bone remodelling sequence.
- Figure 1.9 Duration and depth of the various phases of the normal bone-remodelling sequence.
- Figure 1.10 Current understanding of osteoclastogenesis (OPG/RANKL/RANK System).
- Figure 1.11 Hormonal control of bone resorption.
- Chapter 2 Materials and Methods**
- Chapter 3 Clinical presentation and linkage analysis of IH families**
- Figure 3.1 Pedigree of the New Zealand family.
- Figure 3.2 Radiographs from the youngest affected child (H8).
- Figure 3.3a Normal bone histology.
- Figure 3.3b Bone histology (undecalcified specimen) from the youngest affected child (H8).
- Figure 3.4 Ideogram of chromosome 7.
- Figure 3.5 Ideogram of chromosome 8.
- Figure 3.6 Pedigree of the New Zealand IH Family.
- Figure 3.7 Pedigrees of the families recruited by the IHYP group.
- Figure 3.8 Radiographs of the femur from five individuals with Idiopathic hyperphosphatasia.
- Figure 3.9 Microsatellite analysis of Idiopathic Hyperphosphatasia families recruited by the IHYP collaborative group.
- Chapter 4 Mutation screening of the *TNFRSF11B* gene**
- Figure 4.1 Positions of all five exons on transcript of the *TNFRSF11B* mRNA (NM_002546).
- Figure 4.2 Position of SNPs found within each exon of the *TNFRSF11B* gene and the putative promoter region.
- Figure 4.3 Electrophoretic separation of amplicons encompassing the individual exons of the *TNFRSF11B* gene (A) and the promoter region (B).
- Figure 4.4 Electropherograms of selected sequences of the *TNFRSF11B* gene from families D, E, F, G, H and I.
- Figure 4.5 Genomic organization of the *TNFRSF11B* gene and the location of putative disease-causing mutations.

- Figure 4.6 Representation of functional domains of OPG.
Figure 4.7 Cartoon of the 2nd, 3rd and 4th cysteine-rich ligand-binding domains of OPG.

Chapter 5 FUNCTIONAL ANALYSIS OF *TNFR11B* GENE MUTATIONS

- Figure 5.1 Alignment of human, mouse and , rat amino acid sequences of OPG.
Figure 5.2a Site directed mutagenesis strategy
Figure 5.2b Location of primers and mutations in OPG cDNA.
Figure 5.3 Schematic diagram showing PCR product sequences containing desired mutations.
Figure 5.4 Flow diagram of the construction of plasmid recombinants carrying mutant OPG cDNAs.
Figure 5.5 PCR amplification of mutant OPG cDNA inserts from pcDNA 3.1 constructs.
Figure 5.6 *Eco RI* plus *BamHI* restriction enzyme digestion of plasmid constructs.
Figure 5.7 Electropherograms showing sequence confirmation of plasmid pcDNA 3.1 constructs.
Figure 5.8 RT-PCR total cellular RNA from transfected HEK293 cells.
Figure 5.9 Mutant OPG proteins are hyperglycosylated.
Figure 5.10 OPG variants all fail to inhibit bone resorption *in vitro*.

Chapter 6 Discussion

LIST OF TABLES

Chapter 1	Introduction
Table 1.1	Study of various RANK, OPG and RANKL knock out/over expression mouse models.
Table 1.2	Examples of cytokines and hormones that have their effects mediated through the RANK/OPG/RANKL system.
Table 1.3	Different types of bone disorders resulting from disturbances of the bone remodelling cycle.
Table 1.4	Reported cases of idiopathic hyperphosphatasia.
Chapter 2	Materials and methods
Chapter 3	Clinical presentation and linkage analysis of IH families
Table 3.1	Markers of bone turnover in the New Zealand IH family members.
Table 3.2	Histomorphometric variables measured on iliac bone biopsy of individual H8.
Table 3.3	Microsatellite analysis of the New Zealand family members.
Table 3.4	Clinical details of affected individuals from families recruited by the IHYP group.
Chapter 4	Mutation screening of the <i>TNFRSF11B</i> gene
Table 4.1	Sequence analysis results showing variants found in the five exons of the <i>TNFRSF11B</i> gene and the 2 promoter regions in families A-I.
Chapter 5	Functional analysis of <i>TNFRSF11B</i> gene mutations
Chapter 6	Discussion
	Location of mutations in <i>TNFRSF11B</i> and their predicted effects and relation to phenotype.

ABBREVIATIONS AND SYMBOLS

SI (*S*ystème *I*nternationale d'*U*nités) abbreviations for units and standard notations for chemical elements, formulae, and chemical abbreviations are used throughout this work. Other abbreviations commonly used in the text are listed below.

aa	amino acid
ATP	adenosine triphosphate
bp	base pairs
BSA	bovine serum albumin
cDNA	complementary DNA
CDTA	trans-1,2-diaminocyclohexane- n,n,n',n'- tetraacetic acid
cm	centimetre
dATP	2'-deoxyadenosine 5'-triphosphate
dCTP	2'-deoxycytosine 5'-triphosphate
dGTP	2'-deoxyguanosine 5'-triphosphate
dTTP	2'-deoxythymine 5'-triphosphate
DNA	deoxyribonucleic acid
DNase	deoxyribonuclease
dNTPs	2'-deoxynucleoside 5'-triphosphates
EDTA	ethylenediamine-tetra-acetic acid (disodium salt)
EtBr	ethidium bromide
<i>g</i>	specific gravity
kb	kilobase pairs
kDa	kilodalton
M	moles per litre
mRNA	messenger ribonucleic acid
MW	molecular weight
PBS	phosphate buffered saline

PCR	polymerase chain reaction
®	Registered
RNA	ribonucleic acid
RNase	ribonuclease
rpm	revolutions per minute
SDS	sodium dodecyl sulphate
TAE	Tris-acetate-EDTA buffer
TE	Tris-EDTA buffer
T _m	melting temperature of DNA
™	Trademark
Tris	[2-amino-2-(hydroxymethyl)-propane-1, 3 diol (tris)]
Tris HCl	Tris solution, pH adjusted with HCl
U	units of enzyme (as defined by the manufacturer)
UV	ultraviolet light
v/v	volume per volume
w/v	weight per volume

COMPANY ABBREVIATIONS

The following list contains the abbreviations of suppliers of chemicals, enzymes, and equipment used during the course of this work.

Applied Biosystems	ABI, Foster City, CA, USA
Amersham	Amersham International, Buckinghamshire, UK
BDH	BDH Chemicals NZ Ltd, Palmerston North, NZ
Bio-Rad	Bio-Rad Laboratories, Hercules, CA, USA
Roche Biochemicals Ltd	Roche Biochemicals Ltd, Indianapolis, IN, USA
Genra Systems	Genra Systems Inc, Minneapolis, MN, USA
Life Technologies	Bethesda Research Laboratories, Life Technologies Inc. MD, USA
Perkin Elmer	Perkin Elmer Cetus, CT, USA
Promega	Promega Corporation, Madison, WI, USA
Qiagen	Qiagen GmbH, Hilden, Germany
Riedel-de Haën	Riedel-de Haën, Seelze, Germany
Sigma	Sigma Chemical Company, St Louis, MO, USA
Stratagene	Stratagene Cloning Systems, San Diego, CA, USA

MEDICAL TERMINOLOGY

Acetabular protrusion	Protrusion of the cup-shaped cavity at the base of the hipbone into which the ball-shaped head of the femur fits.
Calcified	To make calcareous by deposit of calcium salts
Cancellous	Having a porous structure made up of intersecting plates and bars that form small cavities or cells
Cartilage	A usually translucent somewhat elastic tissue that composes most of the skeleton of vertebrate embryos and except for a small number of structures (as some joints, respiratory passages, and the external ear) is replaced by bone during ossification in the higher vertebrates
Chondrocytes	A cartilage cell
Collagen	An insoluble fibrous protein of vertebrates that is the chief constituent of the fibrils of connective tissue (as in skin and tendons) and of the organic substance of bones and yields gelatin and glue on prolonged heating with water
Connective tissue	A tissue of mesodermal origin rich in intercellular substance or interlacing processes with little tendency for the cells to come together in sheets or masses
Endocrine system	The glands and parts of glands that produce endocrine secretions, help to integrate and control bodily metabolic activity, and include especially the pituitary, thyroid, parathyroids, adrenals, islets of Langerhans, ovaries, and testes
Endocrinopathy	A disease marked by dysfunction of an endocrine gland
Euchromatic	The genetically active portion of chromatin that is largely composed of genes
Fusiform	Tapering toward each end
Granulocyte	A polymorphonuclear white blood cell (as a basophil, eosinophil, or neutrophil) with granule-containing cytoplasm
Hematopoiesis	The formation of blood or of blood cells in the living body -- called also <i>hemopoiesis</i>
Interferon	Any of a group of heat-stable soluble basic antiviral glycoproteins of low molecular

	weight that are produced usually by cells exposed to the action of a virus, sometimes to the action of another intracellular parasite (as a bacterium), or experimentally to the action of some chemicals, and that include some used medically as antiviral or antineoplastic agents
Interleukin	Any of various compounds of low molecular weight that are produced by lymphocytes, macrophages, and monocytes and that function especially in regulation of the immune system and especially cell-mediated immunity
Kyphoscoliosis	Backward and lateral curvature of the spine
Lymphotoxin	A lymphokine that lyses various cells and especially tumor cell
Macrophages	A phagocytic tissue cell of the mononuclear phagocyte system that may be fixed or freely motile, is derived from a monocyte, and functions in the protection of the body against infection and noxious substances
Monocytes	A large white blood cell with finely granulated chromatin dispersed throughout the nucleus that is formed in the bone marrow, enters the blood, and migrates into the connective tissue where it differentiates into a macrophage
Nervous system	The bodily system that in vertebrates is made up of the brain and spinal cord, nerves, ganglia, and parts of the receptor organs and that receives and interprets stimuli and transmits impulses to the effector organs
Ossified	To form or be transformed into bone
Perichondrium	The membrane of fibrous connective tissue that invests cartilage except at joints
Pleiotropic	Producing more than one genetic effect ; <i>specifically</i> : having multiple phenotypic expressions
Proliferation	Rapid and repeated production of new parts (as in a mass of cells by a rapid succession of cell divisions)
Skeletal system	The bone and cartilages of the body.
Skeleton	A usually rigid supportive or protective structure or framework of an organism ; <i>especially</i> : the bony or more or less cartilaginous framework supporting the soft tissues and protecting the internal organs of

	a vertebrate
Paracrine	Of, relating to, promoted by, or being a substance secreted by a cell and acting on adjacent cells
Pseudoxanthoma elasticum	Pseudoxanthoma elasticum (PXE) is the name given to a group of connective tissue disorders that affects the elastic tissue of the skin, blood vessels, and the eyes. It is also known as Gronblad-Strandberg syndrome.